Read the endpoint behind a longevity claim
Changing a biomarker leaves clinical benefit to be tested. Longevity claims need the trial's intended outcome, with exploratory findings kept in their experimental context.
A blood measurement can improve while a person's daily function stays unchanged. Longevity claims need to specify which outcome was tested.
The proposed sequence starts with a biological feature of aging, then an intervention intended to change it. Showing that the intervention changes the feature leaves its effect on healthy years to be tested.
Senolytics give researchers one way to test that sequence in people. NAD precursors give them another. A mechanism explains a proposed action; a laboratory result measures something that changed. Clinical benefit needs an outcome relevant to the person receiving the intervention.
Identify the trial's primary endpoint
A senolytic aims to remove senescent cells. The proposed action defines a target for an experiment, with any wider effect on human aging requiring further evidence.
A 2024 randomized trial gave intermittent dasatinib plus quercetin to postmenopausal women, with 60 participants in the study. Its primary endpoint was change in a bone-resorption marker at 20 weeks. That endpoint showed no statistically significant difference between groups. Earlier secondary measurements suggested effects, as did exploratory subgroup analyses. The published trial
The result applies to that combination in those participants over the stated period. Exploratory findings can suggest another experiment, while the primary endpoint remains the comparison the trial set out to test.
The National Institute on Aging's February 2025 discussion described mixed results. It left open whether reducing senescent-cell burden would produce meaningful outcomes in people. Strong effects observed in animals still need that human-outcome evidence. NIA's assessment
I'd begin an account of a study with its planned test. That keeps later measurements in context when several results could each supply a headline.
Separate a blood change from clinical benefit
A September 2026 report described a 24-week NMN trial in older adults, using randomization with double blinding against placebo. NAD-related blood metabolites increased. The primary auditory-function endpoint showed no significant improvement, nor did physical-performance measures. Other nominal changes failed correction for multiple testing. The authors described limited broader physiological benefit. The 2026 NMN trial
The company supplying NMN funded the study. Several authors disclosed employment there. Those relationships belong in the assessment of the trial, with the reported findings evaluated on their actual methods.
The intervention changed circulating measurements under those conditions. Showing longer life would require follow-up capable of measuring lifespan. Retained independence needs a relevant functional outcome, while a general aging-reversal claim needs a defined meaning before it can be tested.
The trial also leaves possible uses outside its design unresolved. Its result narrows what can be claimed for this population with these endpoints over 24 weeks.
Preserve the randomized comparison
In a separate long-COVID trial, nicotinamide riboside increased NAD levels. Compared with placebo, cognition showed no significant improvement. Fatigue also showed no significant improvement. Neither sleep nor mood showed a significant improvement. Exploratory analyses found some changes from baseline after combining participants across their treatment periods. The long-COVID trial
A baseline comparison measures change within a person's experience. A randomized comparison also examines what happened to people receiving the control. Symptoms may change over time, while expectations can affect reports. Repeated tests may affect performance too. The control helps account for those alternative explanations.
An exploratory change can identify something to investigate later. Attribution to the treatment depends on the comparison that tests treatment effects against the other explanations.
When reading the result, find the between-group comparison. Then check whether the headline describes it or an exploratory analysis with a different question.
Define the proposed healthspan outcome
Healthspan also needs a measurable definition. A fracture outcome differs from a mobility measure. Preserved cognition needs its own assessment, as do hospital admissions. A trial's findings apply to the outcome its design can examine.
Consider two hypothetical interventions. One changes a blood result substantially without changing daily function. Another produces a modest improvement in an activity participants care about. Choosing between them requires a question about the desired benefit, beyond the size of the laboratory change.
Naming the outcome before reporting a result limits how far the claim can travel. A follow-up study can then test the proposed benefit in the relevant population over a period long enough to observe it.
Personal tracking has limits on attribution too. Changing several interventions while changing sleep habits can make their separate effects difficult to identify. Simultaneous exercise or dietary changes add further explanations for a chart's movement.
State what remains uncertain
My original note compared longevity interventions with software components that could be stacked before being rolled back. That comparison overstated recoverability. Keeping notes about an intervention in a person cannot create a known procedure for reversing its effects.
The engineering habit I'd use is specifying the test before interpreting its result. Name the benefit being sought, then define which finding would weaken the claim. The remaining uncertainty needs an account after the experiment too.
A changed biomarker reports a biological measurement. An exploratory signal can motivate a hypothesis. A demonstrated benefit needs an outcome measured at the scale the claim describes.